Mitral Valve Regurgitation
Conditions
Keywords
ABT-CIP-10337, Tendyne Bioprosthetic Mitral Valve System
Brief summary
The purpose of this study is to evaluate the safety and performance of the Tendyne Mitral Valve System in the treatment of severe mitral regurgitation in patents with functional disability greater than or equal to NYHA Class II, who are not suitable candidates for surgical replacement with otherwise available devices. Follow-up evaluations will be conducted through 5 years post implantation.
Interventions
Patients will undergo transcatheter mitral valve replacement using Tendyne Mitral Valve system
Sponsors
Abbott Medical Devices
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Severe mitral regurgitation of primary or secondary etiology according to MVARC (Mitral Valve Academic Research Consortium) 2015 defined as: * For Degenerative MR: EROA ≥ 40 mm\^2 or regurgitant volume ≥ 60ml * For Secondary MR: EROA ≥ 20 mm\^2 or regurgitant volume ≥ 30ml 2. New York Heart Association (NYHA) functional Class ≥ II while on guideline directed medical therapy (GMDT), including device therapy (CRT) if indicated. 3. Heart team determines patient is not a suitable candidate for traditional surgical treatment according to valid guidelines. 4. Age 18 years or older.
Exclusion criteria
1. Severe mitral annular calcification, severe mitral stenosis, valvular vegetation or mass. 2. Left Ventricle (LV) or Left Atrium (LA) thrombus. 3. Patient has a chest condition that prevents transapical access. 4. Left ventricular ejection fraction (LVEF) less than 30% by echocardiogram. 5. Left Ventricular End Diastolic Diameter (LVEDD) \> 7.0 cm. 6. Prior surgical or interventional treatment of mitral or aortic valves (e.g. valve repair or replacement, MitraClip, edge to edge repair, aortic balloon valvuloplasty, etc.). 7. Any planned surgery or interventional procedure within the period of 30 days prior to 30 days following the implant procedure. This includes any planned concomitant cardiovascular procedure such as PCI, pulmonary vein ablation, left atrial appendage occlusion, septal defect repair, etc. 8. Cardiac resynchronization therapy device or implantable pulse generator implanted within three months of planned implant procedure. 9. Myocardial Infarction (MI) within 30 days of the planned implant procedure. 10. Symptomatic, unresolved multi-vessel coronary artery disease (CAD) or unprotected left main coronary artery disease requiring stenting or Coronary Artery Bypass Grafting (CABG). 11. Cerebrovascular accident (CVA) within six months of planned implant procedure. 12. Unresolved severe symptomatic carotid stenosis (\> 70% by ultrasound). 13. Cardiogenic shock or hemodynamic instability requiring inotropes or mechanical support devices at the time of planned implant procedure. 14. Severe tricuspid regurgitation, tricuspid valve disease requiring surgery or severe right ventricular dysfunction. 15. Hypertrophic or restrictive cardiomyopathy, constrictive pericarditis or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology. 16. Any of the following: leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis, or coagulopathy if cannot be adequately treated. 17. History of endocarditis within six months of planned implant procedure. 18. Active systemic infection requiring antibiotic therapy. 19. Known hypersensitivity or contraindication to procedural or post-procedural medications (e.g., contrast solution, anti-coagulation therapy) which cannot be adequately managed medically or hypersensitivity to nickel or titanium. 20. Patient is undergoing hemodialysis due to chronic renal failure. 21. Patient has pulmonary arterial hypertension (fixed PAS \>70mmHg). 22. Patient has COPD and is on home oxygen. 23. Patient refuses blood transfusions. 24. Pregnant, lactating, or planning pregnancy within next 12 months. 25. Participating or planning participation in an investigational drug or another device study. 26. Patient or legal guardian unable or unwilling to give informed consent. 27. Patient unable or unwilling to comply with study required testing and follow-up visits. 28. Patients with non-cardiac co-morbidities that are likely to result in a life expectancy of less than one year.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety Endpoint: Number of Participants With Composite of Device Success and Freedom From Device or Procedure Related Serious Adverse Events (SAEs) | 30 days post-index procedure | Device success and freedom from the following device- or procedure-related serious adverse events (SAEs) at 30 days post the index procedure, will be classified by the Clinical Events Committee (CEC): * Cardiovascular death * Reintervention caused by valve-related dysfunction * Disabling stroke * Myocardial infarction (MI) * Life-threatening bleeding (BARC Type 2, 3, and 5) * Major Vascular Complications * Renal failure requiring dialysis * Other device-related SAEs * Other procedure-related SAEs |
| Performance Endpoint: Number of Participants With MR Grade ≤ 2 | 30 days post-index procedure | Proportion of subjects with mitral regurgitation (MR) grade ≤ 2, per echocardiography core laboratory will be assessed. MR severity is graded on a scale of 0+ to 4+ where 0+ means absence of mitral regurgitation, 1+ is mild, 2+ is moderate, 3+ is moderate-to-severe and 4+ is severe. |
Countries
Australia, France, Germany, Italy, Netherlands, Norway, Sweden, Switzerland, United Kingdom, United States
Participant flow
Recruitment details
A total of 191 patients were enrolled and attempted TMVR procedure with Tendyne Mitral Valve System. The first subject was implanted on 24 November 2014. The last subject was implanted on 02 June 2020 and completed the 1-month follow-up evaluation on July 6, 2020.
Participants by arm
| Arm | Count |
|---|---|
| Tendyne Mitral Valve System Tendyne Mitral Valve System
Patients will undergo transcatheter mitral valve replacement using Tendyne Mitral Valve system | 191 |
| Total | 191 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Death | 15 |
| Overall Study | Missed Visit | 7 |
| Overall Study | Study Exit | 3 |
Baseline characteristics
| Characteristic | Tendyne Mitral Valve System |
|---|---|
| Age, Continuous | 74.1 years STANDARD_DEVIATION 8 |
| NYHA Class, III/IV | 133 Participants |
| Race/Ethnicity, Customized Asian | 5 Participants |
| Race/Ethnicity, Customized Black or African American | 7 Participants |
| Race/Ethnicity, Customized Caucasian | 177 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 3 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 185 Participants |
| Region of Enrollment Australia | 24 Participants |
| Region of Enrollment France | 18 Participants |
| Region of Enrollment Germany | 22 Participants |
| Region of Enrollment Italy | 20 Participants |
| Region of Enrollment Netherlands | 3 Participants |
| Region of Enrollment Norway | 10 Participants |
| Region of Enrollment Sweden | 1 Participants |
| Region of Enrollment Switzerland | 1 Participants |
| Region of Enrollment United Kingdom | 18 Participants |
| Region of Enrollment United States | 74 Participants |
| Sex: Female, Male Female | 71 Participants |
| Sex: Female, Male Male | 120 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 15 / 191 |
| other Total, other adverse events | 123 / 191 |
| serious Total, serious adverse events | 117 / 191 |
Outcome results
Primary
Performance Endpoint: Number of Participants With MR Grade ≤ 2
Proportion of subjects with mitral regurgitation (MR) grade ≤ 2, per echocardiography core laboratory will be assessed. MR severity is graded on a scale of 0+ to 4+ where 0+ means absence of mitral regurgitation, 1+ is mild, 2+ is moderate, 3+ is moderate-to-severe and 4+ is severe.
Time frame: 30 days post-index procedure
Population: The number of participants analyzed includes subjects who were available at that time of analysis
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tendyne Mitral Valve System | Performance Endpoint: Number of Participants With MR Grade ≤ 2 | 158 Participants |
Primary
Safety Endpoint: Number of Participants With Composite of Device Success and Freedom From Device or Procedure Related Serious Adverse Events (SAEs)
Device success and freedom from the following device- or procedure-related serious adverse events (SAEs) at 30 days post the index procedure, will be classified by the Clinical Events Committee (CEC): * Cardiovascular death * Reintervention caused by valve-related dysfunction * Disabling stroke * Myocardial infarction (MI) * Life-threatening bleeding (BARC Type 2, 3, and 5) * Major Vascular Complications * Renal failure requiring dialysis * Other device-related SAEs * Other procedure-related SAEs
Time frame: 30 days post-index procedure
Population: The number of participants analyzed includes subjects who were available at that time of analysis
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tendyne Mitral Valve System | Safety Endpoint: Number of Participants With Composite of Device Success and Freedom From Device or Procedure Related Serious Adverse Events (SAEs) | 120 Participants |